Clinical Stage Articles & Analysis
36 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to ...
However, these models sometimes failed to predict the proarrhythmic potential of certain compounds, leading to unexpected issues in later drug development stages. CiPA aims to offer a more holistic approach by evaluating multiple ion channels and utilizing advanced in silico modeling, providing a better prediction of cardiac risk. ...
Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. ...
There are currently as many as 25 molecules in the clinical stage, possibly due to its overall good plasma stability, release behavior and chemical towability. ...
Currently, bispecific ADCs are still in the early stages of development globally, with only a few products entering the clinical development stage, and all of them are in early clinical stages. ...
Currently, a number of innovative ADC drug targets have entered the clinical stage worldwide. In the process of research and development of innovative targets, it should be noted that the antigen targets suitable for ADC drugs should have the following characteristics: It is highly expressed in tumor cells and low or no expression in normal tissues. ...
The Development Trend of PROTAC Verify the degradation of "non-druggable proteins" in clinical trials: At present, PROTAC molecules that have entered the clinical trial stage mainly target traditional AR, ER, BTK, etc. ...
Serum enzyme tests have been used in clinical practice for a long time, such as increased amylase activity in serum and urine of patients with acute pancreatitis. ...
The Challenge: With a drug in pre-clinical stage, our client was looking for the first indication to go into clinical ...
For example, the drug developer has initiated four new clinical trials in 2022 alone. It's also a promising sign of strength for investors, although long-term performance will be driven by execution and clinical trial data. ...
Results Our results showed that normal cervical tissues were completely segregated from the cancer samples using about 40 genes whose expressions were significantly different between these specimens. In addition, clinical stage IB and stage IIB tumors could also be classified based on their signature expression patterns. ...
About: CanaQuest Medical is an award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. ...
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem. ...
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s ...
Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 – MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine ...
Recursion is entering an exciting period in our evolution as a clinical-stage biotechnology company. We recently announced that we’ve enrolled the first patient in the first human efficacy trial in our company’s history — a significant milestone for us, and for the patients we hope to serve. ...
Annual planning is an opportunity to fix this long-standing clinical operations issue At the beginning of many pharma companies’ financial year, an annual planning process occurs. This presents an opportunity for stakeholders to align on short-, mid-, and long-term goals. Clinical stage pharma companies focus on ...
Rani Therapeutics, a clinical-stage biotherapeutics company, based in San Jose, CA, is developing orally-administered biologics. ...
In recent years, antibody-drug conjugates (ADCs) have been widely sought after due to their excellent clinical performance and market returns. ADC drugs are composed of three parts: antibody, effector molecule (Payload, usually cytotoxic agent) and linker. ...
Relative to these other options, viral vectors have the advantage of higher delivery efficiency, better targeting, and a long clinical history starting with their use in vaccines and more recently, in gene therapy. ...